{"title":"检查点抑制剂在妇科肿瘤中的作用机制","authors":"Karoutsos Petros, Karoutsos Dimitrios, Karoutsou Eftychia","doi":"10.4172/2157-2518.1000281","DOIUrl":null,"url":null,"abstract":"Currently, immunomodulators are used in different cancer entities, including gynecologic malignancies. Toxicity is variable but of narrow extent. Among immunomodulators, checkpoint inhibitors are used to enhance the immune system and significantly improve therapeutic results of advanced disease, mounting tumor progression.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"3 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer\",\"authors\":\"Karoutsos Petros, Karoutsos Dimitrios, Karoutsou Eftychia\",\"doi\":\"10.4172/2157-2518.1000281\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Currently, immunomodulators are used in different cancer entities, including gynecologic malignancies. Toxicity is variable but of narrow extent. Among immunomodulators, checkpoint inhibitors are used to enhance the immune system and significantly improve therapeutic results of advanced disease, mounting tumor progression.\",\"PeriodicalId\":15209,\"journal\":{\"name\":\"Journal of carcinogenesis & mutagenesis\",\"volume\":\"3 1\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of carcinogenesis & mutagenesis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2157-2518.1000281\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of carcinogenesis & mutagenesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2157-2518.1000281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer
Currently, immunomodulators are used in different cancer entities, including gynecologic malignancies. Toxicity is variable but of narrow extent. Among immunomodulators, checkpoint inhibitors are used to enhance the immune system and significantly improve therapeutic results of advanced disease, mounting tumor progression.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
